PBPatrizio Bollero

Patrizio Bollero

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Patrizio Bollero has a total of 171 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Dentofacial Injuries Associated with E-Scooter Use: A Narrative Review of the International Literature with Descriptive Data from a Prospective Multicenter Italian Clinical Series

    by Luciano Catalfamo, Danilo De Rinaldis, Patrizio Bollero, Raffaella Docimo, Giovanni Bruno, Calogero Scozzaro, Marco Tescione, Francesco Saverio De Ponte, Michele Basilicata

  • Indications, Techniques and Complications Associated With Pterygoid Implants: A Systematic Review and Meta‐Analysis

    by Francesco Gianfreda, Luca Guarente, Marzia Lommi, Maria Scarpati Cioffari di Castiglione, Alberto Antonio Nativio, Carlo Raffone, Mirko Martelli, Patrizio Bollero

    Background and Objectives: Pterygoid implants represent a graftless option for rehabilitation of patients with posterior maxillary atrophy, engaging the dense cortical bone of the pterygomaxillary complex. Despite clinical growth, a comprehensive synthesis of indications, surgical techniques, and complications is lacking. This review evaluated the prevalence of complications, implant survival rates, and marginal bone loss (MBL) associated with pterygoid implant placement. Methods: The reporting of this review follows PRISMA 2020 guidelines. Six electronic databases (PubMed, Ovid, Scopus, WoS, CENTRAL, and Dentistry & Oral Sciences Source) were searched from 1 January 2020 to 31 December 2025. Included criteria comprised randomized and non‐randomized clinical studies reporting outcomes of pterygoid implants (≥ 13 mm) in adult patients with posterior maxillary atrophy (minimum 10 implants). Risk of bias was assessed using JBI critical appraisal checklists. Proportions were pooled using the Freeman‐Tukey double arcsine transformation under a random‐effects model. Certainty of evidence was assessed using GRADE. Results: Seventeen studies reporting 846 patients and 1915 pterygoid implants were included. The pooled survival rate was 97.9% (95% CI: 97.1%–98.6%; I 2 = 0%; 14 studies) and the overall failure rate was 2.1% (95% CI: 1.4%–3.0%). Early failure rate was 0.9% (95% CI: 0.0%–3.0%; I 2 = 59.5%). Late failure and MBL were summarized narratively. Certainty of evidence was low to very low. Conclusions: Pterygoid implants demonstrate excellent survival (97.9%) and low failure rates (2.1%), primarily early, supporting their reliability as a graftless solution for posterior maxillary atrophy. Complications appear infrequent though heterogeneously reported. Low evidence certainty necessitates prospective studies with standardized outcome reporting.

  • Recent Advances in Endocrine, Metabolic and Immune Disorders: Mesenchymal Stem Cells (MSCs) and Engineered Scaffolds

    by Stefania Cantore, Vito Crincoli, Antonio Boccaccio, Antonio Emmanuele Uva, Michele Fiorentino, Giuseppe Monno, Patrizio Bollero, Chiara Derla, Francesca Fabiano, Andrea Ballini, et al.

    Background: New sources of stem cells in adult organisms are constantly emerging. Postnatal Mesenchymal Stem Cells (MSCs), are the most promising support to perform an effective regenerative medicine: such cells have the ability to differentiate into several lineages, such as osteoblasts and chondroblasts, providing novel strategies to improve different complex treatments, during bone regeneration. 3D-printed biomaterials can be designed with geometry aimed to induce stem cells to differentiate towards specific lineage. Objective: The interaction between stem cells easy to isolate and engineered 3D-printed scaffolds can translate the tissue bio-engineering into bone regenerative surgery. For those reasons, to better identify the complexity represented by the activities and responses of MSCs requires the advance of new target therapies which are not current in endocrine, metabolic and immune disorders and yet to be developed. Method: This topical review briefly focuses on the new approaches of translational medicine with the use of MSCs and scaffolds engineered with the aid of 3D-printing technology, highlights the osteogenic functions and addresses their applications across the breadth of regenerative medicine. Results: The application of bone constructs consisting of the engineered scaffold and MSCs as well as the aspects related to the optimal scaffold geometry that favours the best MSCs differentiation and the improvement of concepts as “sensing surface” were also discussed. Conclusion: Regenerative surgery is largely growing in the field of translational medicine. The use of new sources of MSCs and the improvement of new concepts of bio-engineered scaffolds will certainly be the next step of customized medicine.


  • Open Access

    The Role of Platelet‐Rich Fibrin (PRF) in the Prevention of Medication‐Related Osteonecrosis of the Jaw (MRONJ)

    by Michele Miranda, Francesco Gianfreda, Carlo Raffone, Donato Antonacci, Valeria Pistilli, Patrizio Bollero

    Dentoalveolar surgery is probably the major risk factor for MRONJ and for other complications following a tooth extraction, especially in patients affected by systemic diseases. The aim of this retrospective study is to evaluate whether a PRF plug inserted in the post extraction socket can prevent the onset of MRONJ. The patients were divided into two groups according to the surgical protocol that included the insertion or not of the PRF following the extraction and all the anamnestic, and clinical data were analyzed. In the control group, 5 patients developed MRONJ (19.23%) while in the study group, any case of MRONJ was reported. In the control group, patients who developed MRONJ had a CTX with less than 100 pg/mL (5 high‐risk patients, Spearman’s rank r = .547, p < .001). The use of platelet concentrates in patients with high risk of MRONJ is a user‐friendly technique with an excellent cost‐benefit ratio in oral surgery.


  • Open Access

    Melatonin as an index of periodontal disease

    by Rocco Franco, Patrizio Bollero

    Periodontal disease affects the supporting tissues of the tooth. The clinical manifestation varies from gingivitis to periodontitis. Periodontal disease is triggered by bacterial infection that releases toxins. The imbalance between oxidants and antioxidants determines the progression of periodontal disease. Melatonin (MEL) (N-acetyl-5-methoxytryptamine) is a hormone in the human body. Its production takes place in various organs including the retina, gastrointestinal tract, bone marrow, leukocytes, lymphocytes, skin, and principally pineal gland. Its main function is the regulation of circadian and seasonal rhythm, body weight, reproduction, bone metabolism, and tumor growth. An important function of melatonin is the ability to reduce oxidative stress. The aim of this work is to explain if there are differences in salivary melatonin concentration between periodontal and healthy individuals. The study was conducted utilizing the main scientific databases (PubMed, MEDLINE, and Web of Science). The time window considered for the electronic search was from March 1, 2007, to March 1, 2020. The work takes into account 6 works on the disease. Other studies were excluded as they did not meet the inclusion criteria. Studies revealed a concentration of salivary melatonin compared to patients with periodontal disease. Studies agree that the concentration of melatonin is lower in people with periodontal disease. Only one study showed no difference in concentration. Melatonin, therefore, has a protective effect on the periodontium thanks to its antioxidant properties. The salivary measurement of melatonin could be a useful tool for early detection. It can also be used as a therapy to improve the symptoms of periodontal disease.


    • 1 April 2018
      • Vol. 22  (8) , 2191-2198

    Titanium alloy vs. stainless steel miniscrews: an in vivo split-mouth study

    by P. Bollero, V Di Fazio, C. Pavoni, M. Cordaro, P. Cozza, R. Lione

    OBJECTIVE: To compare in vivo Titanium Alloy (TiA) with Stainless Steel (SS) miniscrews Temporary Anchorage Devices (TADs) using removal torque and Scanning Electron Microscopic (SEM) analysis. PATIENTS AND METHODS: 15 subjects (6 males and 9 females) who required maximum anchorage were recruited. For each patient, a TiA TAD and a SS TAD with same length and width were implanted following a randomized splitmouth study design. Retraction was carried out with nickel-titanium spring ligated directly from the anterior hooks of the archwire to the TADs to produce 90 to 100 g of force. When no further anchorage supplementation was needed, the TADs were removed. The removal torque values were registered with a digital screwdriver. After removal, the TADs were collected in a fixed solution and examined using SEM and X-ray microanalysis. RESULTS: All TADs remained intact, with a 100% success rate. There was no difference in removal torque between TiA and SS miniscrews (4.4 +/- 1.3 N-cm and 5.1 +/- 0.7 N-cm, respectively). All specimens' loss of gloss with signs of biological contaminations resulted in a dull implant surface. SEM photomicrographs of TiA miniscrews showed predominantly blood cells while SS miniscrews showed the precipitation of an amorphous layer with low cellular component. There was no difference in spectroscopic analysis between TiA and SS miniscrews. CONCLUSIONS: TiA and SS miniscrews had comparable removal torque values. SEM photomicrographs showed no evidence of osteointegration with both TADs having similar biological responses.


    • 1 February 2018
      • Vol. 22  (4) , 876-887

    Oral management of adult patients undergoing hematopoietic stem cell transplantation

    by P. Bollero, P. C. Passarelli, A. D'Addona, G. Pasquantonio, M. Mancini, R. Condo, L. Cerroni

    Chemotherapy and hematopoietic stem cell transplantation (HSCT) are the current treatments for patients with hematological diseases; they result in myelosuppression, and increase the susceptibility of patients to severe infections. The oral cavity is a potential site of complications in HSCT patients, because it is the entrance for agents that can cause systemic infections; it is one of the most frequent locations for side effects deriving from conditioning therapy. The importance of dental pre-chemotherapy and transplant prescription is often stressed, since both therapies depress the immune system and platelets, making each intervention at this stage a high risk. The aim of this article is to review the potential complications of HSCT, and to extrapolate from the scientific literature the treatments and timeframes in which dental therapies can be performed, avoiding important risks for patients.


    • 1 December 2017
      • Vol. 21  (24) , 5827-5836

    Effects of new probiotic mouthwash in patients with diabetes mellitus and cardiovascular diseases.

    by P Bollero, L Di Renzo, R Franco, T Rampello, A Pujia, G Merra, A De Lorenzo, R Docimo

    To evaluate the impact of a new formulation of probiotic mouthwash (PM), using Biocult strong® dissolved in neutral mouthwash. Forty-two patients with cardiovascular disease (CVD) or type 1 and type 2 diabetes were enrolled. Plaque Control Record (PCR) and Bleeding on Probing (BOP) were assessed at baseline and after two weeks of PM or positive control treatment in intervention group (IG) and control group (CG). Food intake was estimated by 3-day diet record. BOP was significantly reduced in all treatments and samples, except for IG in CVD sample (p=0.15). PCR decreased significantly in all treatments and samples (p<0.01). No significance was obtained for BOP and IP in the time x group interaction. Food intake was not significantly different between IG and CG in all samples. Nutrients such as fats and simple carbohydrates were correlated with BOP in patients who received positive control, rather than PM, indicating a lack of food influence on BOP and PCR in IG. PM treatment was effective in relation to the reduction of PCR and BOP. Probiotics represent a good, but additional, tool for prophylaxis, because they cannot completely substitute the classic oral hygiene methods. Moreover, one week of treatment was not sufficient to draw firm conclusions about the efficacy of the treatment itself.


  • Open Access

    Orthopaedic treatment effects of functional therapy on the sagittal pharyngeal dimensions in subjects with sleep-disordered breathing and Class II malocclusion

    by C. Pavoni, E. Cretella Lombardo, R. Lione, P. Bollero, F. Ottaviani, P. Cozza

    Con il termine Sleep disorder breathing (SDB) s’intendono tutte quelle difficoltà respiratorie che si verificano durante il sonno. Si può osservare una grande variabilità nella sintomatologia dei pazienti affetti da SDB, direttamente proporzionale alla resistenza che le vie aeree superiori offrono al passaggio dell’aria quando queste sono ostruite. L’SDB rappresenta un ampio ventaglio di disturbi che vanno dal russamento primario fino ad arrivare alle apnee ostruttive del sonno. I bambini con problemi respiratori tendono a compensare l’ostruzione delle vie aeree assumendo posizioni caratteristiche, tali da garantire il mantenimento della pervietà delle vie aeree durante il sonno. Un’anomalia di posizione nel sonno, durante la fase di crescita e sviluppo, si ripercuote in un’alterazione dello sviluppo occlusale e in una modifica del pattern di crescita. Le principali alterazioni sono a carico del mascellare superiore, dell’altezza facciale, del tono muscolare e della posizione mandibolare; nei bambini con SDB, infatti, è spesso presente un pattern scheletrico di Classe II, con lunghezza mandibolare ridotta ed overbite aumentato. Lo scopo del presente studio è stato quello di valutare i cambiamenti craniofacciali indotti dalla terapia funzionale di avanzamento mandibolare con particolare riferimento alla dimensione sagittale delle vie aeree, superiori ed inferiori, alla posizione dell’osso ioide e alla posizione della lingua in soggetti con SDB e malocclusione di Classe II, messi a confronto con un gruppo controllo in Classe II non trattato. 51 soggetti (24 femmine, 27 maschi; età media 9,9 ± 1,3 anni) con malocclusione dentoscheletrica di Classe II e SDB trattati con il dispositivo funzionale Monoblocco Modificato (MM) sono stati messi a confronto con un gruppo controllo non trattato di 31 soggetti (15 maschi, 16 femmine; età media 10,1 ± 1,1 anni) presentanti la stessa malocclusione senza SDB. Il gruppo di studio è stato valutato da uno specialista in otorinolaringoiatria per la definizione del tipo di respirazione ed è stato sottoposto ad un esame fisico completo. I genitori di tutti i pazienti hanno completato un questionario per valutare la presenza di sintomi notturni e diurni prima e dopo il test clinico (versione italiana in 22 punti del Pediatric sleep questionnaire, ideato da Ronald Chervin). Le teleradiografie in proiezione latero laterale sono state analizzate all’inizio e alla fine del trattamento con MM. Tutte le misurazioni cefalometriche dei due gruppi sono state analizzate attraverso dei test per la valutazione statistica dei cambiamenti avvenuti durante il trattamento. I risultati hanno evidenziato dei cambiamenti scheletrici favorevoli nel gruppo trattato a tempo T2. La terapia funzionale di avanzamento mandibolare ha indotto dei cambiamenti statisticamente significativi nella dimensione sagittale delle vie aeree, nella posizione dell’osso ioide e nella posizione della lingua in soggetti di Classe II affetti da SDB rispetto ai controlli non trattati. Dopo la terapia ortodontica in 45 pazienti del gruppo di studio è stata osservata una riduzione dei sintomi diurni di SDB. Il trattamento con apparecchiature funzionali, non solo migliora i rapporti tra mascellare superiore e mandibola, ma riduce anche il rischio del collasso delle vie aere superiori. La logica terapeutica si basa sul concetto che tutte le anomalie, legate ad un retroposizionamento mandibolare, beneficiano della terapia funzionale di avanzamento mandibolare, che è in grado di ampliare lo spazio posteriormente alla lingua ed allo stesso tempo promuovere l’avanzamento linguale. Lo spostamento anteriore della mandibola influenza la posizione dell’osso ioide e la posizione della lingua, aumentando lo spazio intermascellare in cui quest’ultima alloggia e migliorando la morfologia delle vie aeree superiori. Ne consegue sia la risoluzione della malocclusione scheletrica di Classe II che il miglioramento dei rapporti retrofaringei, eliminando quei fattori predisponenti per lo sviluppo di disturbi respiratori in età adulta.


  • Open Access

    Evidences of a New Psychobiotic Formulation on Body Composition and Anxiety

    by Carmela Colica, Ennio Avolio, Patrizio Bollero, Renata Costa de Miranda, Simona Ferraro, Paola Sinibaldi Salimei, Antonino De Lorenzo, Laura Di Renzo

    Background. Gut microbiota is implied in obesity, because of its ability to harvest energy from diet, and in the regulation of behavior. Given the link between gut microbiota, body composition, obesity, and anxiety, the aim of this study was to evaluate the effects of a new psychobiotic formulation.Methods. Eligible patients were randomly divided into three groups: psychobiotics oral suspension group (POSG); dietary treatment group (DTG); combined treatment group (CTG). All subjects underwent body composition and psychological profile evaluation.Results. Significant changes in body composition parameters in each group were relieved after all treatments. Hamilton anxiety rating scale (HAM-A) highlighted a significant reduction of the total score for all study population after treatments in POSG (p=0.01) and CTG (p=0.04). A reduction of HAM-A total score in anxious subjects in POSG or CTG and a significant reduction of positive subjects for HAM-A in POSG (p=0.03) and in CDG (p=0.01) were shown.Discussion. Three-week intake of selected POS represents a good approach to solve problems related to obesity and behavior disorders. However, new clinical trials need to be performed on a larger population and for a longer period of treatment before definitive conclusions can be made. This trial is registered withNCT01890070.